BIO-TECHNE Corp (TECH) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2026, BIO-TECHNE reported revenue of $1.22B, down 0.4% from $1.22B the year before. Net income was $181.9M (a 15.0% net margin), or $1.16 per diluted share. Gross margin was 65.8% and operating margin was 20.7%. Operating activities generated $292.1M of cash, leaving $263.2M of free cash flow. At fiscal year end, BIO-TECHNE held $2.59B in total assets against $478.5M in total liabilities, including $264.7M of cash and equivalents.
Open the full interactive BIO-TECHNE financials → Quarterly statements, key ratios, valuation history and price charts.
BIO-TECHNE Key Stats
| Share Price | $72.48 |
|---|---|
| Market Cap | $11.38B |
| P/E Ratio | 62.5 |
| Revenue YoY Growth | -0.4% |
| 52-Week Range | $43.17 – $72.61 |
| Shares Outstanding | 156.0 million (basic, 2026 Q4) |
BIO-TECHNE Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $931.0M | $1.11B | $1.14B | $1.16B | $1.22B | $1.22B |
| Cost of Goods Sold | $298.2M | $349.1M | $366.9M | $389.3M | $429.4M | $416.0M |
| Gross Profit | $632.9M | $756.5M | $769.8M | $769.7M | $790.3M | $799.1M |
| Operating Income | $237.3M | $296.6M | $298.9M | $206.7M | $102.3M | $251.9M |
| Pre-Tax Income | $148.2M | $301.4M | $338.7M | $185.7M | $98.5M | $240.7M |
| Income Tax | $8.6M | $38.3M | $53.2M | $17.6M | $25.1M | $58.8M |
| Net Income | $140.4M | $272.1M | $285.3M | $168.1M | $73.4M | $181.9M |
| Diluted EPS | $0.87 | $1.66 | $1.76 | $1.05 | $0.46 | $1.16 |
BIO-TECHNE Quarterly Results
| 2026 Q1 | 2026 Q2 | 2026 Q3 | 2026 Q4 | |
|---|---|---|---|---|
| Revenue | $286.6M | $295.9M | $311.4M | $321.2M |
| Net Income | $38.2M | $38.0M | $51.0M | $54.6M |
| Diluted EPS | $0.24 | $0.24 | $0.32 | $0.35 |
BIO-TECHNE Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $199.1M | $172.6M | $180.6M | $151.8M | $162.2M | $264.7M |
| Current Assets | $510.6M | $605.6M | $621.5M | $617.4M | $608.3M | $744.4M |
| Total Assets | $2.26B | $2.29B | $2.64B | $2.70B | $2.56B | $2.59B |
| Current Liabilities | $152.3M | $176.0M | $128.5M | $159.4M | $175.8M | $163.7M |
| Total Long-Term Debt | $341.3M | $255.9M | $350.0M | $319.0M | $346.0M | $200.0M |
| Total Liabilities | $700.0M | $593.0M | $672.2M | $635.0M | $639.1M | $478.5M |
| Shareholders' Equity | $1.56B | $1.70B | $1.97B | $2.07B | $1.92B | $2.11B |
BIO-TECHNE Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $352.2M | $325.3M | $254.4M | $299.0M | $287.6M | $292.1M |
| Cash From Investing | -$243.5M | -$96.9M | -$265.6M | -$203.0M | -$35.2M | -$18.2M |
| Cash From Financing | -$62.6M | -$242.9M | $22.6M | -$122.4M | -$253.9M | -$169.1M |
| Free Cash Flow | $307.9M | $280.4M | $216.1M | $236.1M | $256.6M | $263.2M |
Figures from BIO-TECHNE's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full BIO-TECHNE financials page for every line item.
BIO-TECHNE Company Profile
| Ticker | TECH |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Minneapolis, Minnesota |
| Incorporated in | Minnesota |
| Fiscal Year End | June 30 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0000842023 |
Frequently Asked Questions
What was BIO-TECHNE's revenue in fiscal 2026?
BIO-TECHNE (TECH) reported revenue of $1.22B for fiscal 2026.
What is BIO-TECHNE's annual revenue history?
BIO-TECHNE's annual revenue by fiscal year: 2021: $931.0M; 2022: $1.11B; 2023: $1.14B; 2024: $1.16B; 2025: $1.22B; 2026: $1.22B.
What was BIO-TECHNE's net income in fiscal 2026?
BIO-TECHNE reported net income of $181.9M for fiscal 2026.
What was BIO-TECHNE's earnings per share (EPS) in fiscal 2026?
BIO-TECHNE's diluted EPS was $1.16 for fiscal 2026 (adjusted for any later stock splits).
How much free cash flow did BIO-TECHNE generate in fiscal 2026?
BIO-TECHNE generated $263.2M of free cash flow in fiscal 2026.
What was BIO-TECHNE's revenue last quarter?
In its most recent reported quarter (2026 Q4), BIO-TECHNE reported revenue of $321.2M.
How much debt does BIO-TECHNE have?
BIO-TECHNE reported $200.0M of long-term debt, including the current portion, at the end of fiscal 2026.
How many shares of BIO-TECHNE are outstanding?
BIO-TECHNE reported a weighted average of 156.0 million basic shares outstanding in 2026 Q4.
What is BIO-TECHNE's market cap?
Based on its latest closing price, BIO-TECHNE (TECH) has a market capitalization of about $11.38B.
When does BIO-TECHNE's fiscal year end?
BIO-TECHNE's fiscal year end, as registered with the SEC, is June 30.
Where is BIO-TECHNE headquartered?
BIO-TECHNE lists its business address in Minneapolis, Minnesota in its SEC filings.
BIO-TECHNE Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →